[FG] Passweg Jakob

Passweg, J.R. et al. (2024) ‘Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT’, Bone Marrow Transplantation [Preprint]. Available at: https://doi.org/10.1038/s41409-024-02459-0.

Arber, C. et al. (2024) ‘Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data’, Swiss Medical Weekly, 154(10). Available at: https://doi.org/10.57187/s.3704.

Atsuta, Y. et al. (2024) ‘Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors’, Haematologica, 109(10), pp. 3282–3294. Available at: https://doi.org/10.3324/haematol.2024.285002.

Chalandon, Y. et al. (2024) ‘Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms’, Blood Advances, 8(18), pp. 4792–4802. Available at: https://doi.org/10.1182/bloodadvances.2024013468.

Garderet, L. et al. (2024) ‘Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation’, Haematologica, 109(8), pp. 2619–2627. Available at: https://doi.org/10.3324/haematol.2023.284520.

Infanti, Laura (2024) ‘Protecting the blood donor: ferritin-based intervals to improve donor health’, The Lancet, 404(10447), pp. 2–3. Available at: https://doi.org/10.1016/s0140-6736(24)01212-1.

Penack, O. et al. (2024) ‘How risky is a second allogeneic stem cell transplantation?’, Leukemia [Preprint]. Available at: https://doi.org/10.1038/s41375-024-02318-3.

Baldomero, H. et al. (2024) ‘The role of registries in hematological disorders’, Best Practice and Research: Clinical Haematology, 37(2). Available at: https://doi.org/10.1016/j.beha.2024.101556.

Scheid, C. et al. (2024) ‘Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?’, Blood Journal [Preprint]. Available at: https://doi.org/10.1182/blood.2023022273.

Gurnari, C. et al. (2024) ‘Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT’, Blood Advances, 8(6), pp. 1444–1448. Available at: https://doi.org/10.1182/bloodadvances.2023012478.

Sadowska-Klasa, A. et al. (2024) ‘Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL—a report from the EBMT registry’, Bone Marrow Transplantation, 59(3), pp. 387–394. Available at: https://doi.org/10.1038/s41409-023-02192-0.

Manuel, Oriol et al. (2024) ‘Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial’, Clinical Infectious Diseases, 78(2), pp. 312–323. Available at: https://doi.org/10.1093/cid/ciad575.

Codilupi, Tamara et al. (2024) ‘Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable’, Clinical Cancer Research. 01.02.2024, 30(3), pp. 586–599. Available at: https://doi.org/10.1158/1078-0432.ccr-23-0163.

Stivala, Simona et al. (2024) ‘Data from Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable’. American Association for Cancer Research (AACR). Available at: https://doi.org/10.1158/1078-0432.c.7054101.v1.

Bader, Michael Stephan et al. (2024) ‘Minimal residual disease monitoring by Ig/TCR gene rearrangements predicts post-transplant relapse and survival in adult patients with acute lymphoblastic leukemia’, Annals of Hematology [Preprint]. Available at: https://doi.org/10.1007/s00277-024-05943-1.

Baldrich, Adrian et al. (2024) ‘Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 Deficiency’, Journal of Clinical Immunology, 44. Available at: https://doi.org/10.1007/s10875-024-01667-z.

Ben Hassine, Khalil et al. (2024) ‘Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT’, Transplantation and Cellular Therapy, null. Available at: https://doi.org/10.1016/j.jtct.2023.12.003.

Glarner, Noemi et al. (2024) ‘Association of preoperative beta-blocker use and cardiac complications after major noncardiac surgery: a prospective cohort study’, British Journal of Anaesthesia, 132, pp. 1194–1203. Available at: https://doi.org/10.1016/j.bja.2024.02.023.

Guièze, R. et al. (2024) ‘Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT’, Bone Marrow Transplantation [Preprint]. Available at: https://doi.org/10.1038/s41409-024-02256-9.

Heim, Dominik et al. (2024) ‘Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugs’, Swiss Medical Weekly, 154. Available at: https://doi.org/10.57187/s.3754.

Jauch, Annaïse J. et al. (2024) ‘Case report: ‘Atypical Richter transformation from CLL-type monoclonal B-cell lymphocytosis into Burkitt lymphoma in a treatment naïve patient’’, Frontiers in Oncology, 14. Available at: https://doi.org/10.3389/fonc.2024.1296238.

Kusejko, Katharina et al. (2024) ‘Do Infectious Diseases After Kidney Retransplantation Differ From Those After First Kidney Transplantation?’, Open Forum Infectious Diseases, 11(3). Available at: https://doi.org/10.1093/ofid/ofae055.

Ledergerber, Katrin et al. (2024) ‘Impact of Additional Administration of von Willebrand Factor Concentrates to Thrombocyte Transfusion in Perioperative Bleeding in Cardiac Surgery’, Transfusion Medicine and Hemotherapy, 51, pp. 22–31. Available at: https://doi.org/10.1159/000530810.

Loke, Justin et al. (2024) ‘Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study’, Cancer [Preprint]. Available at: https://doi.org/10.1002/cncr.35308.

Maffini, Enrico et al. (2024) ‘Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)’, Bone Marrow Transplantation [Preprint]. Available at: https://doi.org/10.1038/s41409-024-02275-6.

Montoro, Juan et al. (2024) ‘Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT’, Blood [Preprint]. Available at: https://doi.org/10.1182/blood.2024024173.

Nagler, Arnon et al. (2024) ‘Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation’, Bone Marrow Transplantation [Preprint]. Available at: https://doi.org/10.1038/s41409-024-02284-5.

Niederwieser, Christian et al. (2024) ‘Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)’, Bone Marrow Transplantation [Preprint]. Available at: https://doi.org/10.1038/s41409-024-02282-7.

Onida, Francesco et al. (2024) ‘Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT’, British Journal of Haematology, 204, pp. 2365–2377. Available at: https://doi.org/10.1111/bjh.19448.

Passweg, Jakob R. et al. (2024) ‘Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997–2021’, Hematological Oncology, 42. Available at: https://doi.org/10.1002/hon.3241.

Passweg, J.R. et al. (2024) ‘Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT’, Bone Marrow Transplantation [Preprint]. Available at: https://doi.org/10.1038/s41409-024-02248-9.

Penack, Olaf et al. (2024) ‘Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation’, The Lancet Haematology, 11, pp. e147–e159. Available at: https://doi.org/10.1016/S2352-3026(23)00342-3.

Polverelli, Nicola et al. (2024) ‘Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT’, American Journal of Hematology, 99, pp. 993–996. Available at: https://doi.org/10.1002/ajh.27262.

Rafii, Hanadi et al. (2024) ‘Umbilical Cord Blood Transplantation for Fanconi Anemia With a Special Focus on Late Complications: a Study on Behalf of Eurocord and SAAWP-EBMT’, Transplantation and Cellular Therapy, 30, p. 532.e1–532.e16. Available at: https://doi.org/10.1016/j.jtct.2024.02.024.

Robin, M. et al. (2024) ‘Correction to: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT (Bone Marrow Transplantation, (2024), 10.1038/s41409-024-02269-4)’, Bone Marrow Transplantation [Preprint]. Available at: https://doi.org/10.1038/s41409-024-02293-4.

Robin, Marie et al. (2024) ‘Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT’, Bone Marrow Transplantation [Preprint]. Available at: https://doi.org/10.1038/s41409-024-02269-4.

Salas, María Queralt et al. (2024) ‘Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT’, Bone Marrow Transplantation, null. Available at: https://doi.org/10.1038/s41409-023-02159-1.

Schreiber, Peter W. et al. (2024) ‘Surgical site infections after kidney transplantation are independently associated with graft loss’, American Journal of Transplantation, 24, pp. 795–802. Available at: https://doi.org/10.1016/j.ajt.2023.11.013.

Seydoux, Claire et al. (2024) ‘Correction to: Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan (Bone Marrow Transplantation, (2023), 58, 7, (811-816), 10.1038/s41409-023-01963-z)’, Bone Marrow Transplantation, 59, p. 294. Available at: https://doi.org/10.1038/s41409-023-02166-2.

Kleber, M., Ntanasis-Stathopoulos, I. and Terpos, E. (2023) ‘The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma’, Cancers, 15(24). Available at: https://doi.org/10.3390/cancers15245829.

Tettero JM et al. (2023) ‘Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.’, Haematologica, 108(10), pp. 2794–2798. Available at: https://doi.org/10.3324/haematol.2022.282639.

McLornan, D. et al. (2023) ‘Impact of Post-transplant cyclophosphamide (PTCy)-Based Prophylaxis in Matched Sibling Donor Allogeneic Haematopoietic Cell Transplantation for Patients with Myelodysplastic Syndrome: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT’. Research Square Platform LLC. Available at: https://doi.org/10.21203/rs.3.rs-3286332/v1.

Ruutu T et al. (2023) ‘Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study.’, Bone marrow transplantation [Preprint]. Available at: https://doi.org/10.1038/s41409-023-02077-2.

Abou Dalle I et al. (2023) ‘Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.’, Bone marrow transplantation, 58(7), pp. 784–790. Available at: https://doi.org/10.1038/s41409-023-01961-1.

Dertschnig S et al. (2023) ‘Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation.’, Cellular immunology, 388-389, p. 104719. Available at: https://doi.org/10.1016/j.cellimm.2023.104719.

Nagler A et al. (2023) ‘Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT.’, Bone marrow transplantation, 58(7), pp. 791–800. Available at: https://doi.org/10.1038/s41409-023-01980-y.

Radauer-Plank AC et al. (2023) ‘Desire for biological parenthood and patient counseling on the risk of infertility among adolescents and adults with hemoglobinopathies’, Pediatric Blood and Cancer, 70(7), p. e30359. Available at: https://doi.org/10.1002/pbc.30359.

Seydoux C et al. (2023) ‘Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan.’, Bone marrow transplantation, 58(7), pp. 811–816. Available at: https://doi.org/10.1038/s41409-023-01963-z.

Chihara D et al. (2023) ‘Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.’, 108(6). Available at: https://doi.org/10.3324/haematol.2022.281754.

Passweg JR et al. (2023) ‘Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey.’, Bone marrow transplantation, 58(6), pp. 647–658. Available at: https://doi.org/10.1038/s41409-023-01943-3.

Saccardi R et al. (2023) ‘Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE).’, Bone marrow transplantation, 58(6), pp. 659–666. Available at: https://doi.org/10.1038/s41409-023-01924-6.

Ngai LL et al. (2023) ‘Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial.’, Blood, 141(21), pp. 2657–2661. Available at: https://doi.org/10.1182/blood.2022019160.

Rai, S. et al. (2023) ‘IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2 -mutant hematopoietic stem cells’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.05.21.541610.

Greco R et al. (2023) ‘Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party.’, 58(5). Available at: https://doi.org/10.1038/s41409-023-01939-z.

Infanti L (2023) ‘Are we donating iron? Impact of apheresis on ferritin.’, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 62(2), p. 103668. Available at: https://doi.org/10.1016/j.transci.2023.103668.

Penack O et al. (2023) ‘Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party.’, Journal for immunotherapy of cancer, 11(4). Available at: https://doi.org/10.1136/jitc-2022-006406.

Robin M et al. (2023) ‘Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT.’, HemaSphere, 7(4), p. e851. Available at: https://doi.org/10.1097/hs9.0000000000000851.

Tokaz MC et al. (2023) ‘An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.’, Transplantation and cellular therapy, 29(4), p. 279.e1–279.e10. Available at: https://doi.org/10.1016/j.jtct.2022.12.013.

Worel N, Buser A and Körper S (2023) ‘New Trends in Hemapheresis.’, 50(2). Available at: https://doi.org/10.1159/000529738.

Ackermann-Gäumann R et al. (2023) ‘Prevalence of anti-tick-borne encephalitis virus (TBEV) antibodies in Swiss blood donors in 2014-2015.’, Blood transfusion = Trasfusione del sangue, 21(2), pp. 100–109. Available at: https://doi.org/10.2450/2022.0099-22.

Gualandro DM et al. (2023) ‘Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes.’, European journal of heart failure, 25(3), pp. 347–357. Available at: https://doi.org/10.1002/ejhf.2773.

Drozd-Sokolowska J et al. (2023) ‘Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.’, 58(2). Available at: https://doi.org/10.1038/s41409-022-01870-9.

Kloeser R, Buser A and Bolliger D (2023) ‘Treatment Strategies in Anemic Patients Before Cardiac Surgery.’, Journal of cardiothoracic and vascular anesthesia, 37(2), pp. 266–275. Available at: https://doi.org/10.1053/j.jvca.2022.09.085.

Knobel D et al. (2023) ‘Does the age of packed red blood cells, donor sex or sex mismatch affect the sublingual microcirculation in critically ill intensive care unit patients? A secondary interpretation of a retrospective analysis.’, Journal of clinical monitoring and computing, 37(1), pp. 179–188. Available at: https://doi.org/10.1007/s10877-022-00877-3.

Rebmann E et al. (2023) ‘Allogeneic hematopoietic stem cell transplantation in non-Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better.’, EJHaem, 4(1), pp. 258–261. Available at: https://doi.org/10.1002/jha2.614.

Simeunovic H et al. (2023) ‘Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001-2020.’, EJHaem, 4(1), pp. 262–265. Available at: https://doi.org/10.1002/jha2.629.

Herrmann G et al. (2023) ‘Enhancement of the haemostatic effect of platelets in the presence of high normal concentrations of von Willebrand factor for critically ill patients needing platelet transfusion-a protocol for the will-plate randomised controlled trial.’, Trials, 24(1), p. 47. Available at: https://doi.org/10.1186/s13063-022-06876-8.

Badertscher, Patrick et al. (2023) ‘Clinical Utility of D-Dimer for Rule-Out or Rule-In of Venous Thromboembolism in Syncope’, Journal of Cardiovascular Translational Research (JCTR), 16(2), pp. 427–429. Available at: https://doi.org/10.1007/s12265-022-10306-0.

Bänziger S et al. (2023) ‘Feasibility of electronic patient-reported outcome monitoring and self-management program in aplastic anemia and paroxysmal nocturnal hemoglobinuria-a pilot study (ePRO-AA-PNH).’, Annals of hematology, 102(1), pp. 199–208. Available at: https://doi.org/10.1007/s00277-022-05012-5.

Baur, Katharina et al. (2023) ‘CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas’, Bone Marrow Transplantation, 58, pp. 1048–1050. Available at: https://doi.org/10.1038/s41409-023-02016-1.

Chalandon Y et al. (2023) ‘Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.’, American journal of hematology, 98(1), pp. 112–121. Available at: https://doi.org/10.1002/ajh.26764.

Dertschnig S et al. (2023) ‘Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy.’, Transplantation and cellular therapy, 29(1), p. 41.e1–41.e9. Available at: https://doi.org/10.1016/j.jtct.2022.10.029.

Doudesis, Dimitrios et al. (2023) ‘Machine learning for diagnosis of myocardial infarction using cardiac troponin concentrations’, Nature Medicine, 29, pp. 1201–1210. Available at: https://doi.org/10.1038/s41591-023-02325-4.

Jungius, Sarah et al. (2023) ‘Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes’, Frontiers in Oncology, 13. Available at: https://doi.org/10.3389/fonc.2023.1205387.

Junker, Till et al. (2023) ‘Safety and Feasibility of Immunoadsorption with Heparin Anticoagulation in Preparation of ABO-Incompatible Kidney Transplantation: A Retrospective Single-Center Study’, Transfusion Medicine and Hemotherapy, 50, pp. 76–87. Available at: https://doi.org/10.1159/000528261.

Koechlin, Luca et al. (2023) ‘Diagnostic discrimination of a novel high-sensitivity cardiac troponin I assay and derivation/validation of an assay-specific 0/1h-algorithm’, American Heart Journal, 255, pp. 58–70. Available at: https://doi.org/10.1016/j.ahj.2022.10.007.

Koster, Kira-Lee et al. (2023) ‘Prognostic Significance of the Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) in Patients with Myelofibrosis: A Retrospective Study’, Cancers, 15. Available at: https://doi.org/10.3390/cancers15194698.

Luque Paz, Damien et al. (2023) ‘Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms’, HemaSphere, 7(5), p. E885. Available at: https://doi.org/10.1097/hs9.0000000000000885.

Messerich, Nora-Medea et al. (2023) ‘CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70—A Retrospective Study’, Cancers, 15. Available at: https://doi.org/10.3390/cancers15051479.

Nassani M et al. (2023) ‘The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes.’, Frontiers in oncology, 13, p. 1135160. Available at: https://doi.org/10.3389/fonc.2023.1135160.

Ragozzino, Silvio et al. (2023) ‘Epidemiology, outcomes and risk factors for recurrence of Clostridioides difficile infections following allogeneic hematopoietic cell transplantation: a longitudinal retrospective multicenter study’, Bone Marrow Transplantation, null. Available at: https://doi.org/10.1038/s41409-023-02157-3.

Ruggeri, Annalisa et al. (2023) ‘Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation’, Haematologica, 108, pp. 645–652. Available at: https://doi.org/10.3324/haematol.2021.280055.

Sava M et al. (2023) ‘Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates.’, 58(1). Available at: https://doi.org/10.1038/s41409-022-01851-y.

Spyridonidis, A. et al. (2023) ‘Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation’, Bone Marrow Transplantation, null. Available at: https://doi.org/10.1038/s41409-023-02139-5.

Stetka, Jan et al. (2023) ‘Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms’, Blood, 141(17), pp. 2127–2140. Available at: https://doi.org/10.1182/blood.2022017976.

van den Berg, Jana et al. (2023) ‘Von Willebrand factor and the thrombophilia of severe COVID-19: in situ evidence from autopsies’, Research and Practice in Thrombosis and Haemostasis, 7. Available at: https://doi.org/10.1016/j.rpth.2023.100182.

Warthmann, Andrea et al. (2023) ‘BleedHD—a new electronic assessment tool for grading chronic graft-versus-host disease validated in a multicenter and multiprofessional setting’, Bone Marrow Transplantation, 58(5), pp. 613–615. Available at: https://doi.org/10.1038/s41409-023-01945-1.

Worel, Nina et al. (2023) ‘A guide to the collection of T-cells by apheresis for ATMP manufacturing—recommendations of the GoCART coalition apheresis working group’, Bone Marrow Transplantation, 58, pp. 742–748. Available at: https://doi.org/10.1038/s41409-023-01957-x.

Yufera-Sanchez, Ana et al. (2023) ‘Combining glucose and high-sensitivity cardiac troponin in the early diagnosis of acute myocardial infarction’, Scientific Reports, 13. Available at: https://doi.org/10.1038/s41598-023-37093-1.

Forestieri G et al. (2022) ‘Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia.’, 40(5). Available at: https://doi.org/10.1002/hon.3032.

Baron F et al. (2022) ‘Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia.’, Bone marrow transplantation, 57(11), pp. 1657–1663. Available at: https://doi.org/10.1038/s41409-022-01781-9.

Baron F et al. (2022) ‘Correction: Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia.’, 57(11). Available at: https://doi.org/10.1038/s41409-022-01856-7.

Kirsch M et al. (2022) ‘Presence of neoplastic mast cells in ascites in advanced systemic mastocytosis.’, The journal of allergy and clinical immunology. In practice, 10(11), pp. 3035–3038.e1. Available at: https://doi.org/10.1016/j.jaip.2022.07.014.

Nagler A et al. (2022) ‘Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis.’, 28(19). Available at: https://doi.org/10.1158/1078-0432.ccr-22-0809.

Maffini E et al. (2022) ‘Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).’, Bone marrow transplantation, 57(10), pp. 1556–1563. Available at: https://doi.org/10.1038/s41409-022-01748-w.

Raj K et al. (2022) ‘Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT.’, Blood cancer journal, 12(9), p. 140. Available at: https://doi.org/10.1038/s41408-022-00729-y.

Luque Paz, D. et al. (2022) ‘Impact of clonal architecture on clinical course and prognosis in patients with myeloproliferative neoplasms’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2022.09.24.509318.

Dalla Via V et al. (2022) ‘Treosulfan-based Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Adults With Primary Immunodeficiency: A Case Series.’, 42(9). Available at: https://doi.org/10.21873/anticanres.15952.

Medinger M et al. (2022) ‘CB-103: A novel CSL-NICD inhibitor for the treatment of NOTCH-driven T-cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T-ALL.’, 3(3). Available at: https://doi.org/10.1002/jha2.510.

Worel N et al. (2022) ‘Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues.’, The Lancet. Haematology, 9(8), pp. e605–e614. Available at: https://doi.org/10.1016/s2352-3026(22)00184-3.